Literature DB >> 24744393

Human neural stem cells survive long term in the midbrain of dopamine-depleted monkeys after GDNF overexpression and project neurites toward an appropriate target.

Dustin R Wakeman1, D Eugene Redmond2, Hemraj B Dodiya1, John R Sladek1, Csaba Leranth1, Yang D Teng1, R Jude Samulski1, Evan Y Snyder2.   

Abstract

Transplanted multipotent human fetal neural stem cells (hfNSCs) significantly improved the function of parkinsonian monkeys in a prior study primarily by neuroprotection, with only 3%-5% of cells expressing a dopamine (DA) phenotype. In this paper, we sought to determine whether further manipulation of the neural microenvironment by overexpression of a developmentally critical molecule, glial cell-derived neurotrophic factor (GDNF), in the host striatum could enhance DA differentiation of hfNSCs injected into the substantia nigra and elicit growth of their axons to the GDNF-expressing target. hfNSCs were transplanted into the midbrain of 10 green monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine. GDNF was delivered concomitantly to the striatum via an adeno-associated virus serotype 5 vector, and the fate of grafted cells was assessed after 11 months. Donor cells remained predominantly within the midbrain at the injection site and sprouted numerous neurofilament-immunoreactive fibers that appeared to course rostrally toward the striatum in parallel with tyrosine hydroxylase-immunoreactive fibers from the host substantia nigra but did not mature into DA neurons. This work suggests that hfNSCs can generate neurons that project long fibers in the adult primate brain. However, in the absence of region-specific signals and despite GDNF overexpression, hfNSCs did not differentiate into mature DA neurons in large numbers. It is encouraging, however, that the adult primate brain appeared to retain axonal guidance cues. We believe that transplantation of stem cells, specifically instructed ex vivo to yield DA neurons, could lead to reconstruction of some portion of the nigrostriatal pathway and prove beneficial for the parkinsonian condition. ©AlphaMed Press.

Entities:  

Keywords:  GDNF; MPTP; Neural stem cells; Parkinson; Primate; Stem cell; Transplantation

Mesh:

Substances:

Year:  2014        PMID: 24744393      PMCID: PMC4039459          DOI: 10.5966/sctm.2013-0208

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  59 in total

1.  Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.

Authors:  Lars M Bjorklund; Rosario Sánchez-Pernaute; Sangmi Chung; Therese Andersson; Iris Yin Ching Chen; Kevin St P McNaught; Anna-Liisa Brownell; Bruce G Jenkins; Claes Wahlestedt; Kwang-Soo Kim; Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

2.  Cross-species neural grafting in a rat model of Parkinson's disease.

Authors:  A Björklund; U Stenevi; S B Dunnett; F H Gage
Journal:  Nature       Date:  1982-08-12       Impact factor: 49.962

3.  Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca.

Authors:  N A Hillarp; K Fuxe; A Dahlström
Journal:  Pharmacol Rev       Date:  1966-03       Impact factor: 25.468

4.  Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts.

Authors:  K Wictorin; P Brundin; B Gustavii; O Lindvall; A Björklund
Journal:  Nature       Date:  1990-10-11       Impact factor: 49.962

5.  Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats.

Authors:  K Wictorin; P Brundin; H Sauer; O Lindvall; A Björklund
Journal:  J Comp Neurol       Date:  1992-09-22       Impact factor: 3.215

6.  Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease.

Authors:  P Brundin; O G Nilsson; R E Strecker; O Lindvall; B Astedt; A Björklund
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

7.  Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: a comparison with other types of grafts as controls.

Authors:  J R Taylor; J D Elsworth; R H Roth; J R Sladek; T J Collier; D E Redmond
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

8.  Multipotent neural cell lines can engraft and participate in development of mouse cerebellum.

Authors:  E Y Snyder; D L Deitcher; C Walsh; S Arnold-Aldea; E A Hartwieg; C L Cepko
Journal:  Cell       Date:  1992-01-10       Impact factor: 41.582

9.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

10.  Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine.

Authors:  D E Redmond; J R Sladek; R H Roth; T J Collier; J D Elsworth; A Y Deutch; S Haber
Journal:  Lancet       Date:  1986-05-17       Impact factor: 79.321

View more
  12 in total

1.  Tactile Stimulation on Adulthood Modifies the HPA Axis, Neurotrophic Factors, and GFAP Signaling Reverting Depression-Like Behavior in Female Rats.

Authors:  Kr Roversi; Caren Tatiane de David Antoniazzi; L H Milanesi; H Z Rosa; M Kronbauer; D R Rossato; T Duarte; M M Duarte; Marilise E Burger
Journal:  Mol Neurobiol       Date:  2019-02-11       Impact factor: 5.590

Review 2.  Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease.

Authors:  James P Harris; Justin C Burrell; Laura A Struzyna; H Isaac Chen; Mijail D Serruya; John A Wolf; John E Duda; D Kacy Cullen
Journal:  NPJ Parkinsons Dis       Date:  2020-01-08

Review 3.  Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.

Authors:  Yirui Feng; Yu Li; Ping-Ping Shen; Bin Wang
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 5.739

Review 4.  Application and prospects of high-throughput screening for in vitro neurogenesis.

Authors:  Shu-Yuan Zhang; Juan Zhao; Jun-Jun Ni; Hui Li; Zhen-Zhen Quan; Hong Qing
Journal:  World J Stem Cells       Date:  2022-06-26       Impact factor: 5.247

5.  Preferential Heme Oxygenase-1 Activation in Striatal Astrocytes Antagonizes Dopaminergic Neuron Degeneration in MPTP-Intoxicated Mice.

Authors:  Xiaofeng Xu; Ning Song; Ranran Wang; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2015-09-18       Impact factor: 5.590

6.  Melatonin antagonizes interleukin-18-mediated inhibition on neural stem cell proliferation and differentiation.

Authors:  Zheng Li; Xingye Li; Matthew T V Chan; William Ka Kei Wu; DunXian Tan; Jianxiong Shen
Journal:  J Cell Mol Med       Date:  2017-04-21       Impact factor: 5.310

Review 7.  The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neural Transm (Vienna)       Date:  2017-03-22       Impact factor: 3.575

8.  In Vivo Assessment of Cell Death and Nigrostriatal Pathway Integrity Following Continuous Expression of C3 Transferase.

Authors:  Rohan V Gupta; Angel J Santiago-Lopez; Ken Berglund; Robert E Gross; Claire-Anne N Gutekunst
Journal:  Neuroscience       Date:  2020-07-09       Impact factor: 3.708

Review 9.  Stem cell transplantation therapy in Parkinson's disease.

Authors:  Mu-Hui Fu; Chia-Ling Li; Hsiu-Lien Lin; Pei-Chun Chen; Marcus J Calkins; Yu-Fan Chang; Pei-Hsun Cheng; Shang-Hsun Yang
Journal:  Springerplus       Date:  2015-10-13

Review 10.  The Preclinical Research Progress of Stem Cells Therapy in Parkinson's Disease.

Authors:  Jun Zhang; Xianyun Wang; Jing Li; Rui Huang; Xuerui Yu; Ci Dong; Pujuan Liu; Fan Zhang; Jie Hu; Yixin Qi; Jing Zhang; Quanhai Li; Baoyong Yan
Journal:  Biomed Res Int       Date:  2016-06-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.